Discover. Oncology最新文献

{"title":"Comprehensive bioinformatics evaluation uncovers the possible oncogenic contribution of acrylamide to endometrial cancer.","authors":"Yiting Zou, Shan Lu, Shiqiang Han, Renfeng Zhao","doi":"10.1007/s12672-025-03612-x","DOIUrl":"https://doi.org/10.1007/s12672-025-03612-x","url":null,"abstract":"<p><strong>Background: </strong>Endometrial cancer (EC) is a prevalent gynecological malignancy with increasing incidence worldwide. Despite advancements in treatment, challenges such as tumor recurrence and chemoresistance persist. Acrylamide, a probable carcinogen formed in high-temperature cooked foods, has been associated with EC risk, but its oncogenic mechanisms remain underexplored.</p><p><strong>Methods: </strong>Transcriptomic data from GEO datasets (GSE17025, GSE63678, GSE106191, GSE115810) and single-cell RNA sequencing (scRNA-seq) data (PRJNA786266) were integrated to identify differentially expressed genes (DEGs) using the limma package. Acrylamide molecular targets were predicted via SwissTargetPrediction and ChEMBL databases. Machine learning approaches, including LASSO regression, Support Vector Machine (SVM), and Random Forest, were employed to identify key genes. SHAP analysis evaluated gene importance, while ssGSEA assessed immune cell infiltration. Molecular docking experiments investigated acrylamide's binding affinity with key proteins.</p><p><strong>Results: </strong>Differential expression analysis identified 2274 downregulated and 2545 upregulated genes in EC. Nine consensus genes were identified across GEO DEGs, scRNA-seq, WGCNA modules, and acrylamide targets, enriched in Notch, Wnt, and microRNA pathways. Machine learning pinpointed four key genes: ROCK1, CLK1, SIRT1, and PSENEN. SHAP analysis highlighted ROCK1 as the top predictor (AUC = 1.00). ssGSEA revealed significant correlations between these genes and immune cell infiltration, particularly with NK and T cells. Molecular docking confirmed strong binding affinities of acrylamide with CLK1 (- 6.3 kcal/mol), PSENEN (- 6.1 kcal/mol), ROCK1 (- 6.0 kcal/mol), and SIRT1 (- 5.8 kcal/mol).</p><p><strong>Conclusion: </strong>This study elucidates acrylamide's potential oncogenic role in EC, identifying ROCK1, CLK1, SIRT1, and PSENEN as key mediators. These findings underscore the interplay between dietary exposures and EC pathogenesis, suggesting novel therapeutic targets. Further validation is needed to translate these insights into preventive and therapeutic strategies.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1801"},"PeriodicalIF":2.9,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep learning-based survival prediction model for adult diffuse low-grade glioma: a multi-cohort validation study.","authors":"Pengfei Xu, Wenxin Liu, Haibo Su, Tang Ye, Guangyuan Wu, Tao Wu, Baodong Chen","doi":"10.1007/s12672-025-03613-w","DOIUrl":"https://doi.org/10.1007/s12672-025-03613-w","url":null,"abstract":"<p><strong>Background: </strong>Accurate prognostication in adult diffuse low-grade glioma (DLGG) patients remains challenging due to the complex interplay of clinical and molecular factors. This study aimed to develop and validate a deep learning-based model for predicting survival in DLGG patients.</p><p><strong>Methods: </strong>We analyzed 1,079 DLGG patients across three cohorts: training (n = 836), internal validation (n = 210), and external validation (n = 33). A deep learning model (DeepSurv) was developed incorporating seven clinicopathological variables. Model performance was assessed using C-index and integrated Brier scores (IBS). Feature importance was evaluated through permutation importance analysis and SHAP values.</p><p><strong>Results: </strong>The cohorts demonstrated comparable baseline characteristics except for resection extent (P < 0.001). The model achieved robust performance with C-indices of 0.81, 0.76, and 0.87 in the training, internal validation, and external validation cohorts, respectively. Low IBS values (0.03-0.04) confirmed strong predictive accuracy across all cohorts. Age emerged as the strongest prognostic factor, showing non-linear effects particularly pronounced in IDH-wildtype tumors after age 50. IDH mutation status was the second most influential factor, while radiation therapy alone and tumor size showed limited prognostic value.</p><p><strong>Conclusion: </strong>Our deep learning model demonstrates reliable prognostic capabilities for DLGG patients, with age and IDH status as key determinants of survival. The model has been implemented as a web-based platform ( https://seerlggs-f4nze5jr7iuu9k9uuaemjf.streamlit.app ) for clinical use, offering personalized survival predictions. These findings contribute to more precise prognostication and may aid in treatment strategy optimization for DLGG patients.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1802"},"PeriodicalIF":2.9,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing the diagnostic accuracy of pre-operative genetic testing for thyroid cancer on fine needle aspiration cytology specimens: a systematic review and meta-analysis of diagnostic accuracy.","authors":"Xin Liao, Klaas Van Den Heede, Bruno Lapauw, Wouter Huvenne, Dirk Ysebaert, Vanessa Meert, Ying Fang, Jing Li, Sam Van Slycke, Nele Brusselaers","doi":"10.1007/s12672-025-03676-9","DOIUrl":"https://doi.org/10.1007/s12672-025-03676-9","url":null,"abstract":"","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1797"},"PeriodicalIF":2.9,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of FoxP3 in oral squamous cell carcinoma and its biological significance.","authors":"Lina Jiang, Yangxiao Zhang, Chenchen Zhu, Luwen Song, Zhenghao Ma, Hongsheng Liu, Zhenxing Su, Mingxun Xia, Jiancheng Li","doi":"10.1007/s12672-025-03661-2","DOIUrl":"https://doi.org/10.1007/s12672-025-03661-2","url":null,"abstract":"<p><strong>Introduction and objective: </strong>Oral squamous cell carcinoma (OSCC) is a highly malignant tumor that is prone to lymph node metastasis and distant metastasis. FoxP3 is a specific surface marker of regulatory T cells, and its role in various tumors has been confirmed, which is related to tumor progression and prognosis. However, there are relatively few studies on FoxP3 in OSCC, and the role of FoxP3 in OSCC remains unclear.</p><p><strong>Materials and methods: </strong>In this study, the expression of FoxP3 in OSCC was analyzed using data from the TCGA public database. Additionally, 78 OSCC patient samples were analyzed using immunohistochemistry to evaluate the role of FoxP3 in the prognosis of OSCC. The data from TCGA were then investigated using GSEA to explore possible carcinogenic mechanisms. Finally, the online analysis website TIMER was used to analyze the relationship between FoxP3 expression and tumor-associated immune cells.</p><p><strong>Results: </strong>The expression of FoxP3 was up-regulated in OSCC tumor tissues, and the expression level was related to the stage of OSCC. The high expression of FoxP3 was associated with better overall survival. FoxP3 expression was positively correlated with the infiltration level of CD4⁺T cells, CD8⁺T cells, macrophages, neutrophils and dendritic cells.</p><p><strong>Conclusions: </strong>FoxP3 plays an important role in the progression of OSCC and may be related to the prognosis of the tumor.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1800"},"PeriodicalIF":2.9,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gene-edited hematopoietic stem cells for leukemia and lymphoma treatment: a systematic review of preclinical and translational evidence.","authors":"Hassan Nourmohammadi, Mashallah Babashahi, Mohammad Panji, Safa Radmehr","doi":"10.1007/s12672-025-03529-5","DOIUrl":"https://doi.org/10.1007/s12672-025-03529-5","url":null,"abstract":"<p><strong>Background: </strong>Hematopoietic stem cells (HSCs) are pivotal in regenerating the blood and immune systems and have been widely used in treating hematologic malignancies like leukemia and lymphoma. Advances in gene-editing technologies, such as CRISPR/Cas9 and lentiviral vectors, have enabled the modification of HSCs to enhance their therapeutic potential, offering a continuous source of tumor-targeting immune cells. However, challenges related to long-term engraftment, safety, and delivery mechanisms remain.</p><p><strong>Methods: </strong>This systematic review, following PRISMA guidelines, evaluated 19 preclinical and translational studies on gene-edited HSCs for leukemia and lymphoma treatment. The review focused on gene-editing methodologies, preclinical outcomes, delivery challenges, and translational barriers. Databases such as PubMed, Web of Science, and Embase were searched using keywords related to gene editing, HSCs, and hematologic malignancies.</p><p><strong>Findings: </strong>Gene-edited HSCs demonstrated promising preclinical efficacy, with CAR-engineered HSCs showing durable tumor clearance and multilineage immune reconstitution. Lentiviral vectors were the most common delivery method, but concerns about insertional mutagenesis persist. CRISPR/Cas9 offered precise editing but faced challenges with low homology-directed repair (HDR) efficiency in quiescent HSCs. Non-viral delivery methods, such as electroporation, showed potential for safer gene editing but require further optimization. Base editing technologies, while not requiring HDR, present their own delivery challenges that need to be addressed. Suicide gene strategies were effective in mitigating safety risks, while preconditioning regimens improved engraftment success.</p><p><strong>Conclusions: </strong>Gene-edited HSCs hold significant promise for treating leukemia and lymphoma, offering long-term immune persistence and tumor clearance. However, challenges in gene delivery efficiency, safety, and engraftment must be addressed for clinical translation. Future research should focus on improving editing precision, scalable manufacturing, and robust safety monitoring to advance these therapies toward clinical trials.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1804"},"PeriodicalIF":2.9,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-omics-based molecular classification of adrenocortical carcinoma predicts response to immunotherapy and targeted treatments.","authors":"Xingwei Jin, Xianjin Wang, Zhiyuan Wang, Baoxing Huang, Xuejian Zhou, Boke Liu, Yuan Shao, Guoliang Lu","doi":"10.1007/s12672-025-03649-y","DOIUrl":"https://doi.org/10.1007/s12672-025-03649-y","url":null,"abstract":"<p><p>Adrenal cortical carcinoma (ACC) is a rare and highly aggressive malignant tumor with dismal outcomes. Once metastasis occurs, the 5-year survival rate falls below 15%. Current treatment options offer LIMited benefit for advanced disease, Largely due to the absence of well-defined therapeutic targets, and there is an urgent need to develop new molecular classifications to achieve precise treatment strategies. In this study, we integrated multi-omics data including transcriptome, epigenetic, and genomic variation profiles and applied 10 clustering algorithms, identifying two robust molecular subtypes of ACC: Multi-Omics ACC Consensus Subtyping (MACCS)1 and MACCS2. Biologically, MACCS1 exhibits a proliferation-driven phenotype, whereas MACCS2 displays an immune activation state. Drug sensitivity analysis further revealed that MACCS2 tumors were more responsive to immune checkpoint inhibitors, while MACCS1 showed sensitivity to antiangiogenic tyrosine kinase inhibition. Using a random forest algorithm, we identified HOXC11 as a key prognostic factor within MACCS1, with high expression associated with tumor progression. Functional assays confirmed that silencing HOXC11 significantly reduced the proliferation of ACC cells. Survival analysis showed that the prognosis of patients with MACCS1 had markedly worse outcomes compared to those with MACCS2. Collectively, this study provides a theoretical basis for the molecular classification of ACC and personalized precision treatment, such as immunotherapy and targeted therapy, and highlight HOXC11 as a potential therapeutic target.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1803"},"PeriodicalIF":2.9,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of key biomarkers and immune microenvironment features in gliomas based on single-cell analysis combined with bioinformatics.","authors":"Yang Zhang, Lisha Liu, Chao Peng, Lu Wang, Jun Yang, Yingjiang Gu, Yu Cai","doi":"10.1007/s12672-025-03450-x","DOIUrl":"https://doi.org/10.1007/s12672-025-03450-x","url":null,"abstract":"<p><p>Gliomas are highly invasive and heterogeneous tumors in the central nervous system (CNS), characterized by poor prognosis and significant therapeutic challenges. The comprehensive understanding of their molecular mechanisms remains a critical focus and challenge in current research. This study aims to integrate bioinformatics and single-cell analysis technologies to explore glioma-related cell types and immune cell infiltration features, providing new insights into the molecular pathogenesis of gliomas and identifying potential therapeutic targets. Gene expression profiles were selected from Gene Expression Omnibus (GEO), and a glioma-related gene dataset was obtained from GeneCards. Single-cell analysis was employed to identify cell types, and bioinformatics techniques were applied to identify potential pathogenic targets in gliomas. A protein-protein interaction (PPI) network was constructed, followed by functional enrichment analysis using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. Ultimately, drug target prediction and molecular docking analysis revealed the mechanisms of potential drugs. Single-cell analysis identified 10 cell types, with microglial cells and oligodendrocytes playing crucial roles in gliomas. Molecular biological analysis identified 20 key genes. GO and KEGG analyses indicated that these hub genes were primarily enriched in processes such as cellular component organization or biogenesis, cellular processes, cell junctions, and catalytic activity. The main signaling pathways involved include the p53 signaling pathway, cell cycle, and cellular senescence. Furthermore, molecular docking results showed that quercetin effectively binds to four hub targets (DLGAP5, TOP2A, CHEK1, MKI67), suggesting that quercetin may improve glioma-related biological features by acting on these targets. In conclusion, this study not only reveals the significant roles of specific cell types and key genes in gliomas but also preliminarily elucidates the molecular mechanisms of quercetin as a potential therapeutic agent, providing a solid theoretical foundation and new research directions for future glioma intervention strategies.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1798"},"PeriodicalIF":2.9,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbiota and urological cancers: from microecological imbalance to potential for precision therapy.","authors":"Junfeng Cui, Hong Chen, Fengming Dong, Qianqian Zheng, Jinge Wu, Bo Feng, Dongsheng Guo, Shaohui Jiang, Meng Li, Jingyu Li","doi":"10.1007/s12672-025-03296-3","DOIUrl":"https://doi.org/10.1007/s12672-025-03296-3","url":null,"abstract":"<p><p>In recent years, the gut microbiota plays an important role in the occurrence and development of a variety of diseases, especially in the field of oncology, where research progress has become increasingly significant. The complex relationship between urological tumors, such as renal, bladder and prostate cancers, and the gut microbiota has become a hot research topic. The gut microbiota influences the development, progression, and therapeutic response of urological tumors through multiple mechanisms, such as immune regulation, carcinogen metabolism, and chronic inflammation. We summarize the correlation between microbiota imbalance and urological tumors, highlighting the role of specific microbial groups in cancer immunotherapy, especially the synergistic effect in the treatment with immune checkpoint inhibitors (ICIs). Although the impact of the gut microbiota on urological tumors is becoming clearer, challenges remain in how to precisely modulate the microbiota to optimize therapeutic outcomes. Future research should focus on how to improve the therapeutic efficacy and prognosis of urological tumors through personalized dietary interventions, probiotic applications, and the combination of microbiota and drug therapies. These innovative directions provide new ideas for the prevention and treatment of urologic tumors.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1799"},"PeriodicalIF":2.9,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug repurposing in cancer research: a bibliometric analysis.","authors":"Uche Samuel Ndidi, Israel Ogwuche Ogra, Emohchonne Utos Jonathan, Okechukwu Kalu Iroha","doi":"10.1007/s12672-025-02895-4","DOIUrl":"https://doi.org/10.1007/s12672-025-02895-4","url":null,"abstract":"<p><p>Cancer is one of the most pressing global health challenges. Drug repurposing is regarded as the most effective strategy in developing drug candidates by using therapeutic characteristics of well-known drugs. A bibliometric analysis was conducted on drug repurposing in cancer research to assess the current state, focal points, and trends of research aimed at offering a comprehensive overview of research development and providing future research directions in the area. Utilizing the Bibliometrix R package and VOSviewer, this study examined 1166 documents indexed in the Scopus database covering the period from 2008 to 2024. The findings revealed that this field of research is steadily growing with an annual growth rate of 37.49%. The USA and China emerged as the leading contributors to research in this field, with the journals \"Cancers\" and \"Oncotarget\" emerging as the sources with the highest publications and impact, respectively. \"Pantziarka P\" stood out as the most prolific author, while \"Bouche G\" emerged as the most impactful author in drug repurposing in cancer research. Notably, subjects such as \"antineoplastic activity\" garnered considerable attention, highlighting critical research areas within the field. Whereas \"pantoprazole\" and \"transwell assay\" emerged as the latest trending topics in the field. Further investigations into antineoplastic agents, transwell assays, and candidate drugs such as pantoprazole are suggested for shaping the research landscape on cancer drug repurposing. The study offers valuable insights into the trajectory of drug repurposing in cancer research and provides researchers with useful guidance for future exploration of this domain.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1796"},"PeriodicalIF":2.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of KIF14 as a ferroptosis biomarker for predicting the prognosis and immunotherapy efficacy of bladder cancer.","authors":"Xiaocheng Ma, Changyi Quan","doi":"10.1007/s12672-025-03492-1","DOIUrl":"10.1007/s12672-025-03492-1","url":null,"abstract":"<p><strong>Background: </strong>Ferroptosis, a recently recognized form of regulated cell death, plays a prominent role in anti-tumor immunity. However, the potential functions of ferroptosis-related regulators in the prognosis, immune checkpoint genes expression, and immunotherapy efficacy of bladder cancer (BC) have not been systematically studied.</p><p><strong>Materials and methods: </strong>We systematically evaluated the correlations between ferroptosis levels and prognosis, clinical characteristics, tumor mutation burden (TMB), immune checkpoint gene expression, and immune cell infiltration characteristics. The ferroptosis level of each patient was calculated using principal component analysis based on the expression of prognostic differentially expressed genes. Hub ferroptosis-related genes involved in immunoregulation and immunotherapy efficacy in BC were subsequently identified.</p><p><strong>Results: </strong>Eighteen ferroptosis regulators were associated with the prognosis of BC. We identified three ferroptosis subgroups, which have different immune cell infiltration characteristics and distinct carcinogenesis-related immune pathways, such as immune cell differentiation, and the PD-L1/PD-1 pathway. High ferroptosis levels and ferroptosis-related gene kinesin family member 14 (KIF14) are closely associated with poor prognosis, tumor mutation burden, immune checkpoint genes expression, and immune cell infiltration. An immunotherapy cohort confirmed that patients with high KIF14 expression demonstrated significant therapeutic and clinical benefits.</p><p><strong>Conclusions: </strong>The study revealed that ferroptosis level and KIF14 were significantly related to prognosis, immune checkpoint genes expression, immune cell infiltration, and immunotherapy response in BC.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1786"},"PeriodicalIF":2.9,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12484527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}